Pembrolizumab for head and neck cancer

Genomic marker predicts anti-PD-1 response in several cancers

Nivolumab extends survival for NSCLC

Promising results for nivolumab in advanced liver cancer

Nivolumab extends survival for patients with the most common lung cancer

Pembrolizumab shows promising activity against head and neck cancer

Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

Genomic marker predicts anti-PD-1 response in several cancers

'Liquid biopsy' may help earlier detection of lung cancer treatment resistance

Latest in novel approaches to CLL and MCL

Comment: Metastatic triple-negative breast cancer responds to immunotherapy

Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer